Dr. Karl Scheidt earned his B.S. at the University of Notre Dame, where he initiated his research career in the laboratories of Professor Marvin J. Miller. He pursued his graduate studies at Indiana University and the University of Michigan under the guidance of Professor William R. Roush, focusing on reaction development and the synthesis of the natural product bafilomycin A1. Following his graduate research, he served as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor David Evans at Harvard University. In 2002, he joined the faculty at Northwestern University and currently holds a professorship in the Department of Chemistry. He is a fellow of the Alfred P. Sloan Foundation and the Royal Society of Chemistry, an American Cancer Society Research Scholar, and he has received multiple awards from the pharmaceutical industry. Additionally, he co-founded several biotech startup companies focused on translating small molecules into clinical success.